Mutant ras elevates dependence on serum lipids and creates a synthetic lethality for rapamycin

Area of Science:

• Oncology
• Cell Biology
• Metabolic Pathways

Background:

• Cancer cells exhibit altered metabolism, shifting from catabolic to anabolic processes for growth.
• Increased glucose uptake and diversion of intermediates fuel nucleotide, amino acid, and lipid synthesis.
• Serum lipid utilization is an underappreciated nutrient source for cancer cells.

Purpose of the Study:

• To investigate the dependence of human cancer cells on serum lipids.
• To identify potential therapeutic vulnerabilities in Ras-driven cancers related to lipid metabolism.

Main Methods:

• Cultured human cancer cells, specifically Ras-driven types.
• Manipulated serum lipid availability and macropinocytosis.
• Assessed cell proliferation, survival, and sensitivity to rapamycin and mTORC1 inhibition.

Main Results:

• Ras-driven cancer cells exhibit a unique dependence on serum lipids for proliferation and survival.
• Removal of serum lipids sensitizes Ras-driven cancer cells to rapamycin, indicating a synthetic lethal interaction.
• Inhibition of macropinocytosis, a lipid uptake mechanism, also sensitizes Ras-driven cancer cells to mTORC1 suppression.

Conclusions:

• Ras-driven cancers possess a specific metabolic vulnerability related to serum lipid uptake.
• Targeting macropinocytosis or lipid metabolism could be a viable therapeutic strategy for Ras-mutant cancers.
• This metabolic dependency represents a potential Achilles' heel for numerous human cancers driven by Ras mutations.